source
- Abcuro raises $66 million to launch Phase 3 trial in muscle-weakening disease after earlier setbackAbcuro announced it has secured $66 million in financing to support a Phase 3 clinical study targeting a muscle-weakening condition. The funding comes after the company previously reported that it…
- ICER finds AstraZeneca’s blood pressure pill Baxfendy not cost-effective at $10,950 a yearICER released a report saying the clinical benefits of AstraZeneca’s new blood pressure medication Baxfendy do not justify its listed price. The agency noted the drug is priced at $10,950 per pati…